Objective: To use the new consensus definitions of primary progressive multiple sclerosis (PPMS) and progressive relapsing multiple sclerosis (PRMS) to report the demographic, clinical, and natural history characteristics of multiple sclerosis (MS) that is progressive from the time of onset.
I
N 1996, an international survey was conducted to standardize multiple sclerosis (MS) disease course definitions. Consensus emerged 1 for the following terminology. Relapsing-remitting MS describes patients who experience an initial exacerbation followed by complete or incomplete recovery. Although approximately 85% of patients with MS have this disease course within 10 years of the initial attack, 50% develop a gradual progression of disability that may or may not be accompanied by exacerbations; this is called secondary progressive MS. [2] [3] [4] Ten percent to 15% of patients experience a gradual progression of disability from the time of disease onset that is not accompanied by exacerbations 5 ; this is called primary progressive MS (PPMS). Finally a new term, progressive relapsing MS (PRMS), was created to describe patients who experience MS that is progressive from the time of onset and is later accompanied by 1 or more relapses.
There are few studies that describe the characteristics of MS that is progressive from the time of onset, [2] [3] [4] 6, 7 and just 1 article was published after the consensus definitions were proposed. 7 Demographic and clinical characteristics for PPMS were given, but no natural history data were provided, nor was PPMS distinguished from PRMS. The purpose of this study was to apply the new definitions for MS that is progressive from the time of onset and report the natural history, demographic characteristics, and clinical characteristics seen at our tertiary referral center.
RESULTS

PRIMARY PROGRESSIVE MS Diagnosis
Eighty-three (6.9%) of approximately 1200 patients in the clinic database met the con- sensus definition for PPMS. Forty-three patients were diagnosed as having laboratory-supported definite MS (n = 28 for laboratory-supported definite MS B2; n = 15 for laboratory-supported definite MS B3), 8 and 40 were diagnosed with clinically probable MS (n = 26 for clinically probable MS C2; n = 14 for clinically probable MS C3). 8 Subjects with definite and probable MS were similar in sex distribution, age at the time of onset, duration of disease, and rate of progression of disability (data not shown).
Clinical Characteristics
Forty-nine (59%) of 83 patients with PPMS were women. The mean ± SD disease duration from the time of the first symptom was 14.2 ± 8.8 years (median, 12.2 years; range, 1.9-36.4 years). The mean ± SD Expanded Disability Status Scale (EDSS) score at the time of the initial visit was 5.7 ± 2.2 (median, 6; range, 1.5-9.5). The mean ± SD age at the time of the first symptom was 41.2 ± 10.5 years (median, 48 years; range, 17.4-69.4 years) (Figure 1) . There was no relationship between sex and disease duration, EDSS score at the time of the initial visit, or age at the time of the first symptom.
Patients with PPMS experienced 1 or more symptoms at the time of disease onset. The most common initial symptom was weakness (59% [n = 49]). In 94% [n = 78] of these patients, weakness began in 1 leg and was commonly first detected by the patient only upon physical exertion. Cerebellar ataxia was an initial symptom for 24% (n = 20) of this cohort and generally affected the legs as gait imbalance in 85% (n = 71). Other initial symptoms were disturbances of sensation (paresthesias, numbness, or Lhermitte sign) (18% [n = 15]), blurred vision (7% [n = 6]), and urinary dysfunction (4% [n = 3]).
Neurological impairment at time of initial evaluation was categorized by affected Kurtzke functional Thirty subjects (36%) had a syndrome consistent with an isolated myelopathy (ie, absence of ocular, brainstem, or cognitive abnormalities with pyramidal and/or sensory system involvement below the level of the medulla oblongata). Cognitive abnormalities were obvious during patient examination in 5 patients (6%). Neuropsychological testing for lesser degrees of cognitive impairment was not routinely performed as part of this study.
Cerebrospinal Fluid and Paraclinical Studies
Cerebrospinal fluid (CSF) analyses were performed on 54 subjects. Not all CSF parameters were tested on every subject. The white blood cell count ranged from 0 to 50 ϫ 10 9 /L and protein levels ranged from 0.41 to 0.89 g/L; 11% (n = 6) and 10% (n = 5) of subjects had abnormal white blood cell counts and protein levels, respectively. Oligoclonal bands or an elevated IgG index was found in 83% (n = 45) ( Table 1 ). Brain and spinal cord magnetic resonance imaging (MRI) scans demonstrated a focal T 2 -weighted signal consistent with MS in 88% (n = 73) and 47% (n = 39) of the subjects, respectively (Table 1) . Among the 30 patients whose symptoms and signs at the time of the initial clinic evaluation were consistent with a myelopathy, 22 (85%) of 26 had abnormal brain MRI scans and 8 (42%) of 19 had spinal cord MRI scans consistent with MS. Twenty-six subjects completed at least 1 visual evoked potential, brainstem auditory evoked response, or somatosensory evoked response test; although the relative percentage of abnormally prolonged latencies varied from 50% for brainstem auditory evoked response to 68% for visual evoked potential, 85% (n = 22) had abnormally prolonged latencies.
PATIENTS AND METHODS
PATIENTS
The study was approved by the University of California, San Francisco, Committee on Human Research. Medical records were reviewed for all patients who were seen at the University of California, San Francisco/Mount Zion Multiple Sclerosis Center from September 1993 through September 1996. Each patient completed a standardized neurological evaluation. Patients who met consensus criteria for PPMS or PRMS were selected for inclusion in this study. 1 All subjects were interviewed by telephone during a 2-week period with a standardized questionnaire to ascertain the progression of disability since the last clinic visit. When patients were too disabled to cooperate with the interview, a caregiver or close family member was interviewed.
STATISTICAL ANALYSIS
Sex differences for age, age at the time of first symptom, and disease duration were evaluated with the t test. Progression of the disease was evaluated as the time in years required to attain defined end points of disability. Associations between these end points and age at the time of symptom onset or disease duration were evaluated using the Cox proportional hazards model. Associations between level of disability and potential prognostic variables (ie, sex, clinical pattern of MS, impairment by functional system, and the number of impaired functional systems) were evaluated using nonparametric survival analysis stratified by levels of the prognostic factor. Evaluations of impairment by functional systems affected and the number of impaired functional systems were performed for the time of the first symptom and at years 1 through 5.
Progression of Disability
More than 96% of the patients with PPMS (n = 80) experienced difficulty walking after a mean disease duration of 1.1 years and 51% (n = 42) required unilateral gait assistance (EDSS score, 6.0) after 8 years (mean, 10.2 ± 1 years) (Figure 2 and Table 2 ). The mean time required to progress from the need for unilateral gait assistance (EDSS score, 6.0) to the need for bilateral gait assistance (EDSS score, 6.5) was 7.8 years (median, 7 years). The mean time required to progress from the need for bilateral gait assistance to the need for wheelchair assistance (EDSS score, 7.0) was 4.5 years (median, 4 years; 95% confidence interval [CI], 2.2-5.7), and the mean time from the need for wheelchair assistance to the loss of the ability to transfer oneself independently to and from a wheelchair (EDSS score, 8.0) was 12.2 years (median, 10.4 years; 95% CI, 7.7-18.6). There were no differences in the times required to progress to these end points between patients with laboratory-supported definite PPMS or clinically probable PPMS (data not shown).
Predictors of Progression of Disability
The relationships among age, sex, disease duration, first affected functional system, number of first affected functional systems, and time required to reach EDSS scores of 6.0 and 6.5 were analyzed. Disease duration was correlated significantly with progression to EDSS scores of 6.0 (P = .008) and 6.5 (P = .04). The number of involved functional systems 3, 4, and 5 years after symptom onset was correlated with progression to EDSS scores of 6.0 and 6.5 (P = .02 for each), as was bowel and bladder involvement 4 and 5 years after the onset of the first symptom (P = .01 for each). There was no correlation between sex, age at the time of disease onset, first affected functional system, or number of affected functional systems at years 1 and 2 and time required to reach an EDSS score of 6.0 or 6.5.
PROGRESSIVE RELAPSING MS Diagnosis
Twelve (1%) of approximately 1200 patients met the consensus definition for PRMS. 1 Ten were diagnosed as having clinically definite MS and 2 had laboratorysupported definite MS. 
Clinical Characteristics
Eight (67%) of the 12 patients with PRMS were women. The mean ± SD age at the time of the first symptom was 38.0 ± 7.3 years (median, 38.0 years; range, 23.0-49.5 years). The mean ± SD disease duration from the time of the first symptom was 12.2 ± 6.5 years (median, 11.2 years; range, 4.8-26.2 years). The mean ± SD EDSS score at the time of the initial visit was 5.0 ± 2.2 (median, 6.0; range, 0-7.0). There was no relationship between sex and disease duration, EDSS score at the time of the initial visit, or age at the time of the first symptom. These patients with PRMS experienced 1 or more symptoms at the time of MS onset. All had leg symptoms initially, manifesting as weakness (31% [n = 4]), gait imbalance (38% [n = 5]), or numbness or paresthesias (38% [n = 5]). The mean ± SD time to the first exacerbation was 5.5 ± 3 years (range, 8 months to 9 years). The mean ± SD number of acute exacerbations was 1.6 ± 0.5. Five subjects experienced 1 exacerbation and 7 subjects experienced 2 exacerbations. None experienced more than 2 exacerbations. The exacerbations manifested as isolated optic neuritis in 9 patients, optic neuritis with limb paresis in 1, isolated diplopia in 2, diplopia with limb weakness in 1, limb paresis in 3, limb paresis and sensory loss in 1, and isolated limb sensory loss in 2. At the time of the first evaluation at the clinic, the location and frequency of functional system involvement was pyramidal (92% [n = 11]), bowel and bladder (75% 
CSF and Paraclinical Testing
Eleven subjects had an abnormal brain MRI scan and 2 subjects had an abnormal spinal cord MRI scan. Two of 5 subjects had CSF oligoclonal bands or an elevated CSF IgG index.
Progression of Disability and Predictors of Progression of Disability
Seven of the 12 patients reached an EDSS score of 6.0 after 10.9 ± 2.6 years (mean ± SEM), which was not different from patients with PPMS (P = .45). The meaningful assessment of the time required to reach EDSS scores of 6.5, 7.0, and 8.0 or predictors of disease progression was prevented by the small sample size.
COMMENT
In summary, with the exception of 1 or 2 relapses experienced 8 months to 9 years after symptom onset, we could not distinguish PRMS from PPMS. We therefore see little reason to consider them separate clinical entities. This study extends previous observations in patients with PPMS 3, 4, 6, 7, 11 and provides the first detailed description of demographic features, clinical characteristics, and natural history of patients with PRMS. The prevalence of PPMS in our cohort was 6.9%, lower than that of previous reports (range, 9%-37%). [2] [3] [4] 12 Our observations of a 1% PRMS prevalence with rare relapses that were generally not experienced until several years after symptom onset differs markedly from the large retrospective population-based study of Weinshenker et al, 3, 11 who reported a prevalence of 14.8% and a relapse rate of 0.48 during the first 2 years of disease. It is not clear to what extent these differences reflect differences in interpretation of initial symptoms, referral patterns, or genetic heterogeneity. 13 The mean age of symptom onset for both PPMS and PRMS in our study is older than that previously reported for relapsing-remitting patients. 2, 14 It remains unclear whether MS that is progressive from onset represents one end of a broad spectrum of a single disease or whether it is another disease altogether. The latter hypothesis is supported by evidence that PPMS can be distinguished clinically, 1, 15 histopathologically, 16 radiologically, 17 and by immunologic markers 18 from relapsing-remitting MS. Almost all subjects with PPMS and PRMS experienced leg weakness or gait unsteadiness. In contrast, isolated pyramidal findings in the arms were never observed and facial musculature was typically spared when limbs were affected. This pattern of pyramidal findings differs from that observed in relapsingremitting MS. A presentation compatible with a myelopathy was seen in more than one third of the PPMS cohort. This proportion would have risen to 54% if uncorrectable mild visual impairment or the presence of optic disc pallor had been ignored. Evidence of disseminated lesions on brain MRI scans was present in more than 80% of subjects with a purely myelopathic presentation. These observations underscore the importance of a careful ocular examination and brain imaging 19 in the evaluation of myelopathy that is not attributable to spinal cord compression.
There are 4 studies that describe progression of disability in PPMS. Minderhoud et al 2 observed that 7.4% of 128 patients progressed to an EDSS score of 7.0 within 5 years, 30.6% within 15 years, and 62.2% within 25 years. Troiano et al 6 observed that 53% (n = 32) of 60 patients 
